IRIS
BUTI, Sebastiano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.081
AS - Asia 11.057
EU - Europa 6.960
SA - Sud America 2.577
AF - Africa 684
OC - Oceania 21
Continente sconosciuto - Info sul continente non disponibili 9
Totale 32.389
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.743
SG - Singapore 5.783
BR - Brasile 2.031
CN - Cina 1.858
IE - Irlanda 1.567
IT - Italia 1.533
SE - Svezia 1.255
HK - Hong Kong 1.239
VN - Vietnam 1.013
NL - Olanda 613
DE - Germania 503
ZA - Sudafrica 470
FI - Finlandia 226
GB - Regno Unito 224
AR - Argentina 212
AT - Austria 209
IN - India 195
RU - Federazione Russa 194
FR - Francia 181
CA - Canada 148
BD - Bangladesh 147
IR - Iran 126
MX - Messico 115
EC - Ecuador 107
JP - Giappone 84
IQ - Iraq 83
ID - Indonesia 79
TR - Turchia 77
KR - Corea 68
PL - Polonia 64
CO - Colombia 62
BE - Belgio 59
UA - Ucraina 59
ES - Italia 56
CI - Costa d'Avorio 50
PY - Paraguay 48
PK - Pakistan 47
MA - Marocco 44
UZ - Uzbekistan 41
VE - Venezuela 37
EG - Egitto 35
CZ - Repubblica Ceca 33
TN - Tunisia 26
CL - Cile 25
LT - Lituania 25
UY - Uruguay 25
PE - Perù 20
AE - Emirati Arabi Uniti 19
DO - Repubblica Dominicana 18
SA - Arabia Saudita 18
AU - Australia 17
AZ - Azerbaigian 17
DK - Danimarca 17
AL - Albania 15
KE - Kenya 15
RO - Romania 15
KZ - Kazakistan 14
MY - Malesia 14
TW - Taiwan 14
CH - Svizzera 13
IL - Israele 13
TH - Thailandia 13
BG - Bulgaria 12
EE - Estonia 12
JO - Giordania 12
NP - Nepal 12
HN - Honduras 10
OM - Oman 10
BO - Bolivia 9
DZ - Algeria 9
HU - Ungheria 9
LU - Lussemburgo 9
CR - Costa Rica 8
GR - Grecia 8
HR - Croazia 8
PA - Panama 8
PH - Filippine 8
PS - Palestinian Territory 8
SV - El Salvador 8
BH - Bahrain 7
BY - Bielorussia 7
AO - Angola 6
KW - Kuwait 6
MD - Moldavia 6
QA - Qatar 6
RS - Serbia 6
SN - Senegal 6
TT - Trinidad e Tobago 6
KG - Kirghizistan 5
LB - Libano 5
NG - Nigeria 5
XK - ???statistics.table.value.countryCode.XK??? 5
AM - Armenia 4
ET - Etiopia 4
GT - Guatemala 4
JM - Giamaica 4
LV - Lettonia 4
PT - Portogallo 4
BB - Barbados 3
CG - Congo 3
Totale 32.337
Salva come PNG Salva come JPEG
Città #
Singapore 2.704
Chandler 1.909
Dublin 1.552
Ashburn 1.535
Hong Kong 1.223
Dallas 1.142
Santa Clara 990
Boardman 616
Beijing 528
Johannesburg 436
Ho Chi Minh City 384
Princeton 298
Los Angeles 243
Hanoi 233
Shanghai 216
New York 213
Munich 199
Milan 196
São Paulo 191
Vienna 161
Parma 155
Helsinki 126
Ann Arbor 122
Hefei 116
Rome 115
Bologna 103
Nuremberg 103
Des Moines 97
Tehran 92
Moscow 91
Columbus 88
Turku 78
Rio de Janeiro 74
Buffalo 69
Wilmington 69
Tokyo 56
Frankfurt am Main 55
London 53
Montreal 53
Marseille 51
Warsaw 51
Abidjan 50
Bremen 50
Chicago 50
Haiphong 50
Brussels 49
Atlanta 45
Curitiba 45
Jakarta 45
Boston 41
Council Bluffs 41
The Dalles 40
Chennai 39
Seattle 39
Brooklyn 38
Denver 38
Quito 38
Toronto 38
Phoenix 37
Belo Horizonte 36
Brasília 36
Verona 36
Modena 35
Stockholm 34
Tashkent 34
Tianjin 34
Biên Hòa 33
Poplar 33
Seoul 33
Baghdad 32
Guayaquil 32
Pune 32
Genoa 31
Orem 31
San Francisco 31
Guangzhou 30
Amsterdam 29
Da Nang 29
Dearborn 29
Dhaka 29
Jacksonville 26
Mexico City 26
North Bergen 26
Florence 24
Düsseldorf 23
Reggio Emilia 23
Sorocaba 23
Campinas 22
San Jose 22
Asunción 21
Houston 21
Jinan 21
Manchester 21
Montevideo 21
Nanjing 21
Ninh Bình 21
Porto Alegre 21
Fortaleza 20
Secaucus 20
Buenos Aires 19
Totale 18.680
Salva come PNG Salva come JPEG
Nome #
LBA77 Fecal microbiota transplantation (FMT) versus placebo in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma: Preliminary results of the randomized phase II TACITO trial 214
1328P Dynamic blood immune-inflammatory and radiomic profiling to decode distinct patterns of acquired resistance to immunotherapy in NSCLC patients 177
238P Exploring blood immune cell dynamics to unravel the immunomodulatory effect of radiotherapy in NSCLC patients undergoing immune checkpoint inhibitors 176
Correlations between tumor-infiltrating and circulating lymphocyte subpopulations in advanced renal cancer patients treated with nivolumab 175
The Prognostic Role of High Blood Cholesterol in Advanced Cancer Patients Treated With Immune Checkpoint Inhibitors 163
1352P A highly predictive blood-radiomics classifier in advanced NSCLC treated with immunotherapy 163
Immune-based Combinations in Intermediate-/Poor-risk Patients with Non–clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study 160
The circulating pool of functionally competent NK and CD8+ cells predicts the outcome of anti-PD1 treatment in advanced NSCLC 157
PREDICTIVE AND PROGNOSTIC VALUE OF CLINICAL AND MOLECULAR FEATURES IN PATIENTS UNDERGOING PULMONARY METASTASECTOMY FROM RENAL CELL CARCINOMA 154
New hormonal agents and integrated strategies for non-metastatic, hormone-sensitive prostate carcinoma: the orphan setting?—a narrative review 151
External validation of the novel prognostic Meet-URO score in Metastatic Renal Cell Carcinoma on First Line Immune-combination therapy. - Proceedings from the Second International Urology Cancer Summit, 27th September, Portsmouth, UK 145
Immunomodulatory effects of antiangiogenic tyrosine kinase inhibitors in renal cell carcinoma models: Impact on following anti-PD-1 treatments 144
LONGITUDINAL MONITORING OF RADIOMIC AND BLOOD IMMUNE-INFLAMMATORY DESCRIPTORS AS A NON-INVASIVE APPROACH TO PREDICT ICI EFFICACY IN ADVANCED NSCLC PATIENTS 139
17P Dynamic changes of CT-radiomic and systemic immune-inflammatory features predict the response to immune checkpoint inhibitors in advanced NSCLC patients 139
Early primary tumor response in metastatic RCC patients treated with immune checkpoint inhibitors-based combinations 139
Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 137
CLINICAL PREDICTORS OF 30-DAY MORTALITY IN HOSPITALIZED PATIENTS WITH LUNG CANCER: A RETROSPECTIVE SINGLE-CENTER OBSERVATIONAL STUDY 136
The Urinary Microbiome and Anticancer Immunotherapy: The Potentially Hidden Role of Unculturable Microbes 136
CEA and CYFRA 21-1 as prognostic biomarker and as a tool for treatment monitoring in advanced NSCLC treated with immune checkpoint inhibitors 135
Prognostic immunotherapy score (PIS) in patients with advanced urothelial carcinoma treated with pembrolizumab: real-world data and validation from ARON-2 dataset 135
Review on radiological evolution of COVID-19 pneumonia using computed tomography 130
Effectiveness of nivolumab-based immunotherapy and prognostic stratification by the Meet-URO score in real-world older patients with metastatic renal cell carcinoma 129
The role of blood cholesterol quality in patients with advanced cancer receiving immune checkpoint inhibitors 129
READY: Real-world data from an Italian compassionate use program of avelumab first-line maintenance (1LM) treatment for locally advanced or metastatic urothelial carcinoma (la/mUC) 128
1929O Soluble PD-L1 and circulating CD8+PD1+ and NK cells enclose a highly prognostic and predictive immune effector score in immunotherapy treated NSCLC patients 128
ALK and ROS1 rearrangements tested by fluorescence in situ hybridization in cytological smears from advanced non-small cell lung cancer patients 128
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC 125
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma 125
Chronically administered immunotherapy with low-dose IL-2 and IFN-α in metastatic renal cell carcinoma: A feasible option for patients with a good prognostic profile 124
Resistance to osimertinib in advanced EGFR-mutated NSCLC: a prospective study of molecular genotyping on tissue and liquid biopsies 123
Soluble PD-L1 and Circulating CD8+PD-1+ and NK Cells Enclose a Prognostic and Predictive Immune Effector Score in Immunotherapy Treated NSCLC patients 123
Antibiotic-dependent effect of probiotics in patients with non-small cell lung cancer treated with PD-1 checkpoint blockade 120
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events 120
Circulating immune-profile as predictor of outcome in advanced NSCLC patients treated with Nivolumab 120
Intersecting Blood Cytokines With Cholesterol Parameters to Profile Patients With Advanced Solid Tumors Receiving Immune Checkpoint Inhibitors 118
1901P Specific dynamic changes of peripheral blood immune profile (PBIP) associate with clinical response to nivolumab (NIVO) in patients (pts) with metastatic renal cell carcinoma (mRCC): The I-RENE trial (meet-URO 8) 116
Author Correction: Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients (Scientific Reports, (2019), 9, 1, (13218), 10.1038/s41598-019-49250-6) 116
Analysis of a panel of druggable gene mutations and of ALK and PD-L1 expression in a series of thymic epithelial tumors (TETs) 114
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity 113
INfluenza Vaccine Indication during therapy with Immune checkpoint inhibitors: A multicenter prospective observational study (INVIDIa-2) 113
Immunotherapy options in metastatic renal cell cancer: Where we are and where we are going 113
Fecal microbiota transplantation to improve efficacy of immune checkpoint inhibitors in renal cell carcinoma (TACITO trial) 113
Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first-line immunotherapy-based regimens 112
Changes in lymphocyte count induced by repeated cycles with low-dose interleukin-2 and interferon-α in 146 patients with renal cell carcinoma. 111
Monitoring cfDNA in plasma and in other liquid biopsies of advanced EGFR mutated NSCLC patients: A pilot study and a review of the literature 108
91 Circulating lipid profile as a prognostic factor in patients with advanced solid tumors treated with immune checkpoint inhibitors 107
7 Tamoxifen vs tamoxifen plus 13-cis-retinoic acid vs tamoxifen plus interferon α-2° as first-line endocrine treatments in advanced breast cancer: updated results of a phase II, prospective, randomized multicentre trial 107
Clinical Impact of COVID-19 Outbreak on Cancer Patients: A Retrospective Study 106
Clinical parameters for first-line immuno-combinations choice in metastatic renal cell carcinoma (mRCC) patients (pts): the Meet-URO 33 study 104
Palliative radiotherapy in advanced cancer patients treated with immune-checkpoint inhibitors: The practice study 103
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab 102
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors 102
Molecular classification using Lund University algorithm and clinical correlations in muscle-invasive bladder cancer: Insights from a retrospective study 101
Differential diagnosis of COVID-19 at the chest computed tomography scan: A review with special focus on cancer patients 101
The Role of CT Imaging in Characterization of Small Renal Masses 99
Unraveling the link between cholesterol and immune system in cancer: From biological mechanistic insights to clinical evidence. A narrative review 99
P1.15-04 Dynamic Profiling of Blood Immunophenotypes and Radiomic Features to Predict Immunotherapy Response in Advanced Non-small Cell Lung Cancer 99
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy 99
Cabozantinib in metastatic renal cell carcinoma: Latest findings and clinical potential 98
Combined standard immunosuppression and immune checkpoint inhibition for BKPyV+ metastatic renal cell carcinoma of the graft in a kidney transplant recipient with chronic rejection: a case report 97
The prognostic value of the haemoglobin/red cell distribution width ratio in a cohort of pre-treated patients with renal cell carcinoma receiving nivolumab 96
BOLERO-3 results: Pharmacological activity or pharmacokinetic effect? 96
Abscopal effect after hypofractionated radiotherapy in metastatic renal cell carcinoma pretreated with pazopanib 96
Oxaliplatin-induced hemolytic anemia during adjuvant treatment of a patient with colon cancer: A case report 96
Role of Chemotherapy With Gemcitabine Plus 5-fluorouracil and Chemoimmunotherapy in Metastatic Renal Cell Cancer (mRCC) 95
A wide skull osteolytic metastasis in advanced breast cancer 95
Antiangiogenic tyrosine kinase inhibitors and immunotherapy as first-line treatment for metastatic renal cell carcinoma: is there an increased risk of hypothyroidism? 95
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-α for metastatic renal cell cancer 95
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study 95
The effect of concomitant drugs on oncological outcomes in patients treated with immunotherapy for metastatic urothelial carcinoma: a narrative review 94
Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50% 94
Gefitinib plus interleukin-2 in advanced non-small cell lung cancer patients previously treated with chemotherapy 94
Real world analysis of peritoneal metastasis from renal cell carcinoma: Meet-Uro 27 study 93
LA PRATICA CLINICA - Everolimus nel carcinoma renale papillare 93
P254 REAl-world Data from an Italian Compassionate Use Program (CUP) of avelumab first- Line Maintenance (1LM) for locallY advanced or metastatic Urothelial Carcinoma (la/mUC): Outcomes from the READY study in patients (pts) with low tumor burden 92
2125P Potential ROle of hypoVItaminosis D in patiENts with cancer treated with immune ChEckpoint inhibitors (PROVIDENCE): A prospective observational study 92
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 92
The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients 92
Tamoxifen vs Tamoxifen plus 13-cis-retinoic acid vs Tamoxifen plus Interferon α-2a as first-line endocrine treatments in advanced breast cancer: Updated results of a phase II, prospective, randomised multicentre trial 92
Long-term clinical results with low-dose interleukin-2 and interferon-alpha in 145 patients with metastatic renal cell carcinoma” (Poster) 91
Avelumab Maintenance for Urothelial Carcinoma 91
Upper Tract Urinary Carcinoma: A Unique Immuno-Molecular Entity and a Clinical Challenge in the Current Therapeutic Scenario 90
Retroperitoneal cystoadenocarcinoma: A case report with a literature review 90
Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib 89
1462P Clinical outcome of patients with non-clear metastatic renal cell carcinoma treated with pembrolizumab-axitinib combination: NEMESIA (non-clear metastatic renal cell carcinoma pembrolizumab axitinib) study, a subgroup analysis of I-RARE observational study (Meet-URO 23a) 89
Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study 89
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced urothelial carcinoma (UC) or non-UC variant histologies (VH) after platinum chemotherapy: Interim results from the phase 2 ARCADIA trial. 88
1599P Clinical predictors of 30-day mortality in hospitalized patients with lung cancer: A retrospective single-center observational study 87
Phase III, randomised, multicentre trial of maintenance immunotherapy with low-dose interleukin-2 and interferon-alpha for metastatic renal cell cancer 87
External Validation of the GRade, Age, Nodes and Tumor (GRANT) Score for Patients with Surgically Treated Papillary Renal Cell Carcinoma 87
1476P Immunohistochemical (mIHC) analyses of the immune tumor microenvironment (I-TME) in metastatic renal cell carcinoma (mRCC) patients (pts) receiving immunotherapy: Main results from the Meet-URO 18 study 86
Retrospective analysis of patients undergoing stereotactic body radiotherapy (SBRT) in secondary non-bone lesions of metastatic renal cell carcinoma (mRCC) in treatment with vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors 86
Chemotherapy, targeted therapy and immunotherapy: Which drugs can be safely used in the solid organ transplant recipients? 86
BONSAI-2 study: Nivolumab as therapeutic option after cabozantinib failure in metastatic collecting duct carcinoma patients 85
THE ROLE OF BLOOD CHOLESTEROL QUALITY IN PATIENTS WITH ADVANCED CANCER RECEIVING IMMUNE CHECKPOINT INHIBITORS 85
Cabozantinib in the elderly with metastatic renal cell carcinoma undergoing geriatric G8 screening test: A prospective multicenter observational study (ZEBRA/MEET-URO 9) 85
A metanalysis on cabozantinib and bone metastases: True story or commercial gimmick? 85
Very late recurrence of an apparently benign pheochromocytoma 85
Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors 84
Combining PARP Inhibitors and Androgen Receptor Signalling Inhibitors in Metastatic Prostate Cancer: A Quantitative Synthesis and Meta-analysis 84
Totale 11.214
Salva come PNG Salva come JPEG
Categoria #
all - tutte 144.788
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 144.788
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021150 0 0 0 0 0 34 13 19 37 19 16 12
2021/20221.466 9 10 13 30 5 117 319 100 61 25 100 677
2022/20236.059 710 740 558 380 457 586 80 316 1.925 27 203 77
2023/20242.659 135 225 103 109 290 542 204 125 178 154 189 405
2024/202510.042 157 697 754 408 903 1.145 418 456 1.254 1.204 727 1.919
2025/202612.208 1.633 1.890 3.179 2.016 2.965 525 0 0 0 0 0 0
Totale 33.019